The Oncology Business Unit at Pfizer UK will consider high-quality submissions for independent medical education programmes, independent general research, and quality improvement initiatives in the following areas:

Lung Cancer

• Aligned to issues identified by UK Government, NICE, PAGs (for example Macmillan, ALK+UK, Roy Castle Lung Cancer Foundation) in health care inequalities or innovations in tackling these to improve outcomes in patients in the scope of this strategy

• Evidence generation for relevant oncogene-driven lung cancers, particularly the UK pathway based on Real World Data (RWD)

• Health services research for lung cancers in the NHS setting, including improvement in patient pathways

• Projects exploring new models of care, such as, digital patient initiatives that improve clinician-patient communication and patient treatment experience, patient safety and/or adherence to therapy

• Innovations to tackle health care inequalities and improve outcomes of patients and carers affected by lung cancer

• Projects optimising healthcare delivery, quality improvement and patient care in relation to lung cancers

• Mechanisms to manage patients away from hospital and/or reduce hospital attendances

• Initiatives to increase education of patients in disease areas as well as innovative mechanisms to distribute patient education

• Initiatives to increase education of healthcare professionals (HCPs) working in lung cancer

• Initiatives to improve testing for oncogene-driven lung cancers

Breast Cancer

• Aligned to issues identified by UK Government, NICE, PAGs (for example Macmillan, Breast Cancer Now) in health care inequalities or innovations in tackling these to improve outcomes in patients

• Support programmes/initiatives for the underserved population; low socioeconomic, ethnic minorities, LGBTQIA+ and others on the special register

• Mechanisms to manage patients away from hospital/reduce hospital attendances

• Initiatives to increase education of patients in disease areas as well as innovative mechanisms to distribute patient education

• Initiatives to support the metastatic breast cancer (mBC) national audit

• Novel concepts to overcome resistance pathways in ER+ HER2- BC (estrogen receptor positive, human epidermal growth factor 2 negative breast cancer)

• Real world evidence in measuring efficacy and safety in special populations

• Education of HCPs in the UK to improve patient outcomes which are above brand or across disease for example: breast cancer educational session, multidisciplinary teaching sessions, communication skills related education, breast cancer research sessions, ovarian cancer research session etc

• Initiative in line with the NHS Life Sciences Vision 

Genitourinary (GU)

• Evidence generation for bladder, prostate, renal cancer and ovarian cancers particularly the UK pathway based on Real World Data (RWD)
• Health services research for bladder, prostate, renal and ovarian cancers in the NHS setting, including improvement in patient pathways
• Projects exploring new models of care, such as, digital patient initiatives that improve clinician-patient communication and patient treatment experience, patient safety and/or adherence to therapy in GU-Oncology
• Basic science research investigating mechanisms relating to PARP inhibition prostate and ovarian cancers and Immuno-Oncology (IO) in GU-cancers
• Research developing individualised treatment strategies in bladder, prostate, renal and ovarian cancers
• Projects optimising healthcare delivery, quality improvement and patient care in relation to bladder, prostate, renal and ovarian cancers
• Mechanisms to manage GU-Oncology patients away from hospital and/or reduce hospital attendances
• Initiatives to increase education of patients in GU-Oncology disease areas as well as innovative mechanisms to distribute patient education
  

Haematology

• Aligned to issues identified by UK Government, NICE, PAGs (for example Macmillan, Blood Cancer UK, Leukaemia Care) in health care inequalities or innovations in tackling these to improve outcomes in patients in the scope of this strategy

• Services or education to support early diagnosis of Blood Cancers

• Services or education to improve psychological support and post treatment physical care.

• COVID-19 related patient initiatives to decrease inequality in healthcare

• Educational gaps identified by educational and research bodies in the UK

• Education of HCPs in the UK to improve patient outcomes all above brand or across disease for example: haematology educational session, multidisciplinary teaching sessions, acute myeloid leukaemia research sessions, myeloma research session etc.

• Clinician or patient educational tools to help manage disease in COVID-19

• Patient educational videos/resources on blood cancer management

• Education or services tailored specifically to explaining blood cancer diagnosis to children, or family and carers

• Education or services signposting patients to available support for people living with blood cancer

• Education or services related to infertility and fertility preservation for chemotherapy

• Education or services related to chemotherapy induced early menopause

• Education or services empowering patients to access clinical research information and clinical trials

• Real World Evidence generation for haematological malignancies focussed in the UK

Examples may include grant requests to support independent accredited education, quality improvement or research that are intended to improve patient outcomes in areas of unmet medical need.

For all independent medical grants, the grant recipient is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Pfizer must not be involved in any aspect of project development, nor its conduct or monitoring.

To discuss your potential independent medical grant application for any of the above areas, please phone 01304 616161 and ask to speak to a member of the oncology medical affairs team.